619296-47-8

Upstream product

• 2941-78-8 2-Amino-5-methylbenzoic acid 
• 313545-32-3 (2-chloro-6-fluorophenyl)boronic acid 

Downstream Products

• 1403226-60-7 C₁₆H₁₅ClFNO₂ 
• 1175086-67-5 2-[(2-chloro-6-fluorophenyl)amino]-5-methylbenzeneacetic acid methyl ester 
• 1403226-61-8 C₁₅H₁₄ClFN₂O₂ 
• 1403226-62-9 C₁₆H₁₃ClFN₃O₂ 
• 1403226-63-0 C₁₆H₁₅ClF₄N₂O₂S 
• 1403226-64-1 N-(2-chloro-6-fluorophenyl)-4-methyl-2-(1H-tetrazol-5-ylmethyl)-benzenamine 
• 1403226-79-8 C₁₄H₁₄ClFN₂ 
• 1403226-66-3 N-[[2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl]methyl]-1,1,1-trifluoromethanesulfonamide 
• 1403226-56-1 2-[(2-chloro-6-fluorophenyl)amino]-5-methylbenzeneacetonitrile 
• 220991-20-8 lumiracoxib 
• 1403226-77-6 C₁₅H₁₆ClFN₂ 

Relevant academic research and scientific papers

In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition

Purpose Patients with high cardiovascular risk due to ageing and/or comorbidity (diabetes, atherosclerosis) that require effective management of chronic pain may take advantage from new non-steroidal anti-inflammatory drugs (NSAIDs) that at clinical dosag

Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors

A series of lumiracoxib derivatives were designed to explore the influence of isosteric substitution on balancing COX-2 inhibition and thromboxane A2 prostanoid (TP) receptor antagonism. The compounds were synthesized through a copper-catalyzed coupling procedure and characterized for their pKa values. TP receptor antagonism was assessed on human platelets; COX-2 inhibition was determined on human isolated monocytes and human whole blood. TPα receptor binding of the most promising compounds was evaluated through radioligand binding assays. Some of the isosteric substitutions at the carboxylic acid group afforded compounds with improved TP receptor antagonism; of these, a tetrazole derivative retained good COX-2 inhibitory activity and selectivity. The identification of this tetrazole acting as a balanced dual-acting compound in human whole blood, along with SAR analysis of the synthesized lumiracoxib derivatives, might contribute to the rational design of a new class of cardioprotective anti-inflammatory agents.